Proclara Biosciences Announces Newly Issued U.S. Patents for its Core Technology Targeting Protein Misfolding Disorders

CAMBRIDGE, Mass., Nov. 16, 2016 – Proclara Biosciences, a biotechnology company developing novel therapies for diseases caused by protein misfolding, today announced that the U.S. Patent and Trademark Office has issued two new patents related to the company’s proprietary General Amyloid Interaction Motif (GAIM) platform. Proclara’s GAIM-based therapies enable the simultaneous targeting of multiple misfolded proteins implicated in neurodegenerative diseases.

The newly issued patents (U.S. Patent Nos. 9493515 and 9493516) broadly cover Proclara’s core technology, including methods of treating protein misfolding diseases and pharmaceutical compositions comprising the company’s lead molecule, NPT088, a GAIM-Ig fusion protein currently being evaluated in a Phase 1b study for the treatment of Alzheimer’s disease. The patents also cover second and third generation GAIM-based therapeutic candidates currently in preclinical testing for other protein misfolding diseases of the central nervous system, including Alzheimer’s, Parkinson’s and tauopathies, and in peripheral amyloidoses. The patents have a statutory expiration date in 2034.

“Receipt of these patents marks a significant milestone for Proclara, providing broad and powerful protection of our core technology while underscoring the innovative nature of our novel approach to treating protein misfolding disorders,” said Richard Fisher, Ph.D., Chief Scientific Officer of Proclara. “As we advance our pipeline, we are continuing to extend our patent estate, including additional patent applications related to our GAIM technology platform.”

About Proclara Biosciences

Proclara Biosciences is a biotechnology company advancing product candidates developed based on proprietary GAIM technology, which is capable of simultaneously targeting multiple toxic misfolded proteins. The broad applicability of the Proclara technology enables the company to target multiple protein misfolding diseases, including neurodegenerative diseases and several rare systemic amyloidoses. The lead GAIM drug candidate, NPT088, is in clinical development for the treatment of Alzheimer’s disease. For more information, please visit

Media Contact
Sarah Sutton
Ten Bridge Communications
(857) 242-1619

Investor Contact 
Hannah Deresiewicz
Stern Investor Relations, Inc.
(212) 362-1200